Get the Stockscreener App
0.00
100.00%
-0.5242
Klotho Neurosciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
See More
Previous Close:
$0.5242
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$56.66M
Revenue:
-
Net Income/Loss:
$-11.35M
P/E Ratio:
0.00
EPS:
-0.4554
Net Cash Flow:
$-5.51M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$3.9099
Klotho Neurosciences Inc Stock (KLTO) Company Profile
Name
Klotho Neurosciences Inc
Sector
Industry
Phone
(833) 931-6330
Address
13576 WALNUT STREET, SUITE A, OMAHA
Compare KLTO vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLTO
Klotho Neurosciences Inc
|
0.00 | 56.66M | 0 | -11.35M | -5.51M | -0.4554 |
VRTX
Vertex Pharmaceuticals Inc
|
442.89 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.45 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
703.38 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.33 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.38 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Klotho Neurosciences Inc Stock (KLTO) Latest News
Klotho Neurosciences expands into mining with Greenland mines deal - MSN
Klotho Neurosciences advances epigenetic diagnostics with development of AI-driven "Klotho Clock" - MSN
Greenland Mines locks in rare icebreaker as 2026 Arctic base - Stock Titan
Nasdaq grants Greenland Mines (GRML) 180-day extension to regain $1 bid price compliance - Stock Titan
Greenland Mines secures additional 180-day period for Nasdaq bid price compliance - marketscreener.com
Greenland Mines Secures Additional 180-Day Period for Nasdaq Bid Price Compliance - Yahoo Finance
What is the current Price Target and Forecast for Klotho Neurosciences, Inc. (GRML) - Zacks Investment Research
Greenland Mines Engages WSP Denmark to Launch Comprehensive Environmental Baseline Program at Skaergaard Mining Site - Carroll County Mirror-Democrat
Two-year Arctic survey starts as Greenland mine pursues permit - Stock Titan
Klotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene Therapy - MSN
Short Covering: What are Klotho Neurosciences Inc Equity Warrants growth levers2026 Year in Review & Growth Focused Entry Reports - baoquankhu1.vn
GRML: Klotho Neurosciences, Inc.Comparative Chart - Zacks Investment Research
Winners Losers: Is Klotho Neurosciences Inc likely to announce a buybackCEO Change & AI Driven Stock Price Forecasts - baoquankhu1.vn
GRML : Klotho Neurosciences, Inc. Key Company Details - Zacks Investment Research
GRML : Klotho Neurosciences, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Greenland Mines Rebrands and Launches Dual-Focus Strategy - TipRanks
Greenland Mines Ltd (Nasdaq: GRML) rebrands and outlines dual divisions - Stock Titan
Klotho Neurosciences, Inc. (GRML) Debt Equity Ratio (Quarterly) - Zacks Investment Research
All News for GRML : Klotho Neurosciences, Inc. - Zacks Investment Research
Klotho Neurosciences acquires Greenland palladium-gold project By Investing.com - Investing.com Nigeria
Klotho Neurosciences, Inc. (GRML) Total Expenses (Quarterly) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Total Liabilities - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Book Value - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Cash From Operations (TTM) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Return On Equity (TTM) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Gross Margin (TTM) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Shareholders Equity (Quarterly) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Profit Margin (Quarterly) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Return On Assets (TTM) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Free Cash Flow (Quarterly) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Revenue (Quarterly) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Book Value (Per Share) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Enterprise Value - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Dividend (TTM) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Cash From Financing (Quarterly) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Revenue (TTM) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Gross Profit (TTM) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Market Cap - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Cash From Operations (Quarterly) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Price To Free Cash Flow - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Price - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Total Long Term Debt (Quarterly) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Total Expenses (TTM) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Price To Cash Flow - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Cash From Financing (TTM) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Net Income (Quarterly) - Zacks Investment Research
Greenland Mines Ltd Cash Flow – NASDAQ:GRML - TradingView
Klotho Neurosciences, Inc. (GRML) Cash Equivalents (Quarterly) - Zacks Investment Research
Klotho Neurosciences, Inc. (GRML) Total Assets (Quarterly) - Zacks Investment Research
Klotho Neurosciences Inc Stock (KLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):